公开(公告)号：US11957675B2

公开(公告)日：2024-04-16

申请号：US17668340

申请日：2022-02-09

Applicant: XENON PHARMACEUTICALS INC.

Inventor： Simon Neil Pimstone

IPC: A61K31/472 ,  A61P25/24

CPC classification number: A61K31/472 ,  A61P25/24

Abstract: The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US12171759B1

公开(公告)日：2024-12-24

申请号：US18604727

申请日：2024-03-14

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Simon Neil Pimstone

IPC: A61K31/472 ,  A61P25/24

Abstract: The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20240408076A1

公开(公告)日：2024-12-12

申请号：US18604727

申请日：2024-03-14

Applicant: Xenon Pharmaceuticals Inc.,

Inventor： Simon Neil Pimstone

IPC: A61K31/472 ,  A61P25/24

Abstract: The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.